CA2351315C - Anticorps humanise specifique pour l'antigene de surface pre-s1 de hbv et son procede de preparation - Google Patents

Anticorps humanise specifique pour l'antigene de surface pre-s1 de hbv et son procede de preparation Download PDF

Info

Publication number
CA2351315C
CA2351315C CA002351315A CA2351315A CA2351315C CA 2351315 C CA2351315 C CA 2351315C CA 002351315 A CA002351315 A CA 002351315A CA 2351315 A CA2351315 A CA 2351315A CA 2351315 C CA2351315 C CA 2351315C
Authority
CA
Canada
Prior art keywords
fwdarw
humanized
amino acid
seq
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002351315A
Other languages
English (en)
Other versions
CA2351315A1 (fr
Inventor
Hyo Jeong Hong
Chun Jeih Ryu
Hyangsuk Hur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Green Cross Corp
Korea Advanced Institute of Science and Technology KAIST
Original Assignee
Korea Green Cross Corp
Korea Advanced Institute of Science and Technology KAIST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Green Cross Corp, Korea Advanced Institute of Science and Technology KAIST filed Critical Korea Green Cross Corp
Publication of CA2351315A1 publication Critical patent/CA2351315A1/fr
Application granted granted Critical
Publication of CA2351315C publication Critical patent/CA2351315C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des anticorps humanisés spécifiques pour l'antigène pre-S1 de surface de HBV, qui montrent une affinité similaire à l'anticorps monoclonal de la souris, ainsi qu'une immunogénicité remarquablement diminuée, étant donné qu'ils possèdent moins de résidus aminoacides dérivés de la souris. Ces anticorps humanisés peuvent, de ce fait, être utiles pour la prévention de l'infection par HBV et pour le traitement de l'hépatite B.
CA002351315A 1998-11-19 1999-11-19 Anticorps humanise specifique pour l'antigene de surface pre-s1 de hbv et son procede de preparation Expired - Fee Related CA2351315C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1998/49663 1998-11-19
KR19980049663A KR100345463B1 (ko) 1998-11-19 1998-11-19 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
PCT/KR1999/000699 WO2000031141A1 (fr) 1998-11-19 1999-11-19 Anticorps humanise specifique pour l'antigene de surface pre-s1 de hbv et son procede de preparation

Publications (2)

Publication Number Publication Date
CA2351315A1 CA2351315A1 (fr) 2000-06-02
CA2351315C true CA2351315C (fr) 2006-01-24

Family

ID=37037248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002351315A Expired - Fee Related CA2351315C (fr) 1998-11-19 1999-11-19 Anticorps humanise specifique pour l'antigene de surface pre-s1 de hbv et son procede de preparation

Country Status (8)

Country Link
US (1) US7115723B1 (fr)
EP (1) EP1131358B1 (fr)
JP (1) JP3552103B2 (fr)
KR (1) KR100345463B1 (fr)
AT (1) ATE285418T1 (fr)
CA (1) CA2351315C (fr)
DE (1) DE69922834D1 (fr)
WO (1) WO2000031141A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1151010T3 (da) * 1999-02-05 2006-01-09 Therapeutic Human Polyclonals Humane polyklonale antistoffer fra antigene ikke-humane dyr
EP1604997A1 (fr) * 1999-02-05 2005-12-14 Therapeutic Human Polyclonals, Inc. Anticorps humains polyclonaux d'animaux génétiquement modifiés
EP1322761A4 (fr) * 2000-10-02 2005-03-23 Korea Res Inst Of Bioscience Anticorps humanise dirige contre l'antigene s de surface du virus de l'hepatite b et procede de preparation de ce dernier
KR100455902B1 (ko) * 2001-07-18 2004-11-12 주식회사 펩트론 Ｂ형 간염 바이러스 표면단백질 프리에스-1 유래의 펩타이드
EP1532175B1 (fr) * 2002-03-22 2012-10-17 Aprogen, Inc. Anticorps humanise et procede de preparation correspondant
ES2916174T3 (es) 2002-05-02 2022-06-28 Wyeth Holdings Llc Conjugados de transportador derivado de caliqueamicina
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
CN100582781C (zh) * 2006-06-27 2010-01-20 厦门大学 联合检测hbv前s1抗原和核心抗原的方法及诊断试剂盒
CN101506235B (zh) 2006-09-01 2012-07-25 人类多细胞株治疗学公司 人或人源化免疫球蛋白在非人转基因动物中增强的表达
KR101864693B1 (ko) * 2014-11-27 2018-06-07 진원생명과학 주식회사 B형 간염 바이러스의 preS1에 특이적으로 결합하는 항체 및 이의 용도
KR102558839B1 (ko) 2015-03-25 2023-07-25 아이쥐엠 바이오사이언스 인코포레이티드 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도
JP6820278B2 (ja) * 2015-05-22 2021-01-27 フアフイ ヘルス リミテッドＨｕａｈｕｉ Ｈｅａｌｔｈ Ｌｔｄ． 抗Ｐｒｅ−Ｓ１ ＨＢＶ抗体
CA3145057A1 (fr) * 2019-07-20 2021-01-28 Wenhui Li Procede de traitement d'une infection par le virus de l'hepatite b a l'aide d'anticorps anti-vhb pre-s1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202796D0 (en) 1992-02-11 1992-03-25 Wellcome Found Antiviral antibody

Also Published As

Publication number Publication date
JP2002531073A (ja) 2002-09-24
KR100345463B1 (ko) 2003-01-08
US7115723B1 (en) 2006-10-03
CA2351315A1 (fr) 2000-06-02
DE69922834D1 (de) 2005-01-27
WO2000031141B1 (fr) 2000-07-20
KR20000033008A (ko) 2000-06-15
JP3552103B2 (ja) 2004-08-11
ATE285418T1 (de) 2005-01-15
EP1131358B1 (fr) 2004-12-22
EP1131358A1 (fr) 2001-09-12
WO2000031141A1 (fr) 2000-06-02

Similar Documents

Publication Publication Date Title
KR100708398B1 (ko) 인간화 항체 및 이의 제조방법
US7332582B2 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CA2351315C (fr) Anticorps humanise specifique pour l'antigene de surface pre-s1 de hbv et son procede de preparation
EP3978521A1 (fr) Anticorps anti-pre-s1 du virus de l'hépatite b (hbv)
JP2013515477A (ja) Ｂ型肝炎ウイルス表面抗原に特異的に結合するヒト抗体
CN115087673A (zh) 结合il4r的抗体及其用途
KR100789645B1 (ko) Ｂ형 간염바이러스의 ｓ-표면항원을 인식하는 인간화 항체및 이의 제조방법
JP2004517636A (ja) Ｂ型肝炎ウイルスの表面抗原ｓに対するヒト化抗体及びその製造方法
KR100308758B1 (ko) Ｂ형 간염 바이러스의 표면항원 프리-ｓ2에 대한 인간화 항체 및그의 제조방법
KR100191900B1 (ko) B형 간염바이러스의 표면항원 s에 대한 인간화항체 및 이의 제조방법
KR0163163B1 (ko) B형 간염 바이러스의 표면항원 pre-S2에 대한 인간화 항체 및 이의 제조방법
US20030096403A1 (en) Humanized antibody to surface antigen s of hepatitis b virus and a preparing method thereof
KR100345469B1 (ko) B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
TW202204396A (zh) 抗hbv抗體及使用方法
CN115724985A (zh) 一种cdc平台抗体
KR20040058606A (ko) 비형간염바이러스의 에스-표면항원을 인식하는 인간화항체 및 이의 제조방법

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed